Literature DB >> 27251644

The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.

Shozo Okamoto1, Tohru Shiga2, Koichi Yasuda3, Shiro Watanabe1, Kenji Hirata1, Ken-Ichi Nishijima4, Keiichi Magota1, Katsuhiko Kasai1, Rikiya Onimaru3, Kazuhiko Tuchiya3, Yuji Kuge4, Hiroki Shirato3, Nagara Tamaki1.   

Abstract

PURPOSE: The purpose of this study was to prospectively investigate reoxygenation in the early phase of fractionated radiotherapy and serial changes of tumoricidal effects associated with intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer (HNC) using F-18 fluoromisonidazole (FMISO) PET and F-18 fluorodeoxyglucose (FDG) PET.
METHODS: Patients with untreated HNC underwent FMISO-PET and FDG-PET studies prospectively. A PET evaluation was conducted before each IMRT (Pre-IMRT), during IMRT (at 30 Gy/15 fr) (Inter-IMRT), and after completion of IMRT (70 Gy/35 fr) (Post-IMRT). FMISO-PET images were scanned by a PET/CT scanner at 4 h after the FMISO injection. We quantitatively analyzed the FMISO-PET images of the primary lesion using the maximum standardized uptake (SUVmax) and tumor-to-muscle ratio (TMR). The hypoxic volume (HV) was calculated as an index of tumor hypoxia, and was defined as the volume when the TMR was ≥ 1.25. Each FDG-PET scan was started 1 h after injection. The SUVmax and metabolic tumor volume (MTV) values obtained by FDG-PET were analyzed.
RESULTS: Twenty patients finished the complete PET study protocol. At Pre-IMRT, 19 patients had tumor hypoxia in the primary tumor. In ten patients, the tumor hypoxia disappeared at Inter-IMRT. Another seven patients showed the disappearance of tumor hypoxia at Post-IMRT. Two patients showed tumor hypoxia at Post-IMRT. The FMISO-PET results showed that the reduction rates of both SUVmax and TMR from Pre-IMRT to Inter-IMRT were significantly higher than the corresponding reductions from Inter-IMRT to Post-IMRT (SUVmax: 27 % vs. 10 %, p = 0.025; TMR: 26 % vs. 12 %, p = 0.048). The reduction rate of SUVmax in FDG-PET from Pre-IMRT to Inter-IMRT was similar to that from Inter-IMRT to Post-IMRT (47 % vs. 48 %, p = 0.778). The reduction rate of the HV in FMISO-PET from Pre-IMRT to Inter-IMRT tended to be larger than that from Inter-IMRT to Post-IMRT (63 % vs. 40 %, p = 0.490). Conversely, the reduction rate of the MTV in FDG-PET from Pre-IMRT to Inter-IMRT was lower than that from Inter-IMRT to Post-IMRT (47 % vs. 74 %, p = 0.003).
CONCLUSIONS: Both the intensity and the volume of tumor hypoxia rapidly decreased in the early phase of radiotherapy, indicating reoxygenation of the tumor hypoxia. In contrast, the FDG uptake declined gradually with the course of radiotherapy, indicating that the tumoricidal effect continues over the entire course of radiation treatment.

Entities:  

Keywords:  FDG-PET; FMISO-PET; Head and neck cancer; Radiotherapy; Reoxygenation; Tumor hypoxia

Mesh:

Substances:

Year:  2016        PMID: 27251644     DOI: 10.1007/s00259-016-3431-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

1.  Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI.

Authors:  Piet Dirix; Vincent Vandecaveye; Frederik De Keyzer; Sigrid Stroobants; Robert Hermans; Sandra Nuyts
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

2.  Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.

Authors:  Christina Schütze; Ralf Bergmann; Kerstin Brüchner; Birgit Mosch; Ala Yaromina; Daniel Zips; Franziska Hessel; Mechthild Krause; Howard Thames; Jörg Kotzerke; Jörg Steinbach; Michael Baumann; Bettina Beuthien-Baumann
Journal:  Radiother Oncol       Date:  2014-03-14       Impact factor: 6.280

Review 3.  Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review.

Authors:  Gyorgy B Halmos; Leonie Bruine de Bruin; Johannes A Langendijk; Bernard F A M van der Laan; Jan Pruim; Roel J H M Steenbakkers
Journal:  Clin Nucl Med       Date:  2014-01       Impact factor: 7.794

Review 4.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

Review 5.  Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited.

Authors:  Frank Pajonk; Erina Vlashi; William H McBride
Journal:  Stem Cells       Date:  2010-04       Impact factor: 6.277

6.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Yoichi M Ito; Keiichi Magota; Katsuhiko Kasai; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

8.  Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change.

Authors:  J K Hoang; S K Das; K R Choudhury; D S Yoo; D M Brizel
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-07       Impact factor: 3.825

9.  Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice.

Authors:  C Petersen; W Eicheler; A Frömmel; M Krause; S Balschukat; D Zips; M Baumann
Journal:  Int J Radiat Biol       Date:  2003-07       Impact factor: 2.694

10.  [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.

Authors:  Koichi Yasuda; Rikiya Onimaru; Shozo Okamoto; Tohru Shiga; Norio Katoh; Kazuhiko Tsuchiya; Ryusuke Suzuki; Wataru Takeuchi; Yuji Kuge; Nagara Tamaki; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-13       Impact factor: 7.038

View more
  7 in total

1.  Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer.

Authors:  Aya Asano; Shigeto Ueda; Ichiei Kuji; Tomohiko Yamane; Hideki Takeuchi; Eiko Hirokawa; Ikuko Sugitani; Hiroko Shimada; Takahiro Hasebe; Akihiko Osaki; Toshiaki Saeki
Journal:  Breast Cancer Res       Date:  2018-07-27       Impact factor: 6.466

2.  [18F]Fluoromisonidazole PET in rectal cancer.

Authors:  Tanuj Puri; Tessa A Greenhalgh; James M Wilson; Jamie Franklin; Lia Mun Wang; Victoria Strauss; Chris Cunningham; Mike Partridge; Tim Maughan
Journal:  EJNMMI Res       Date:  2017-09-20       Impact factor: 3.138

3.  Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.

Authors:  Markus Kroenke; Kenji Hirata; Andrei Gafita; Shiro Watanabe; Shozo Okamoto; Keiichi Magota; Tohru Shiga; Yuji Kuge; Nagara Tamaki
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

4.  Interim 4'-[methyl-11C]-thiothymidine PET for predicting the chemoradiotherapeutic response in head and neck squamous cell carcinoma: comparison with [18F]FDG PET.

Authors:  Katsuya Mitamura; Takashi Norikane; Yuka Yamamoto; Kengo Fujimoto; Yasukage Takami; Hiroshi Hoshikawa; Jun Toyohara; Yoshihiro Nishiyama
Journal:  EJNMMI Res       Date:  2021-02-10       Impact factor: 3.138

5.  Synthesis and Preliminary Evaluation of a Novel 18F-Labeled 2-Nitroimidazole Derivative for Hypoxia Imaging.

Authors:  Jing Lu; Chi Zhang; Xi Yang; Xi-Juan Yao; Qun Zhang; Xin-Chen Sun
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

Review 6.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

Review 7.  Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy.

Authors:  Jian Jian Li
Journal:  iScience       Date:  2020-05-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.